Sophie Lucas obtained a Ph.D. in 2000 in the field of tumour immunology at the UCLouvain (with Pr. Thierry Boon).
In 2004 after a research spell at Genentech, US, she founded her own research group at the de Duve Institute, UCLouvain, Brussels, BE. Dr Lucas and her team then discovered how the transmembrane protein GARP binds, presents and activates TGF-β on the surface of human Regulatory T cells,Tregs. Monoclonal antibodies directed against GARP:TGF-β were subsequently developed and are currently tested in clinical trials as novel cancer immunotherapy candidates.

Eric is a serial biotech entrepreneur with a proven track record of deal-making and fund-raising (€160 millions so far). He was also instrumental in bringing 4 drug candidates from research to the clinics (up to phase IIb). Eric had numerous successes in the sale and initial public offering of biotech companies. Eric co-founded Myosix (acquired by Genzyme in 2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved cell therapy mobile manufacturing unit.
Eric holds master degrees in Pharmacology and in Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

In 2014, Dr Joël Plumas, PhD, an internationally renowned onco-immunologist, co-founded PDC*line Pharma from the French Blood Bank (EFS, Etablissement Français du Sang, Grenoble, Fr) to further develop and bring innovative cancer vaccines to market by exploiting the PDC*vac technology he co-invented whilst at the EFS. The PDC*vac technology harnesses allogeneic plasmacytoid dendritic cells to prime and boost anti-tumor cytotoxic cells in cancer patients.
Prior to PDC-Line Pharma, Joël was the Director of the Cancer Immunobiology and Immunotherapy R&D lab at the EFS. During this tenure and using the PDC*vac technology, Joël and his team successfully developed from bench to bedside the first-in-human clinical trial in stage IV melanoma patients. Joël has contributed so far to over 110 articles and papers in the medical literature and filed 3 patents.

Javier was trained in translational research in the field of immuno-oncology at the Ludwig Institute for Cancer Research, Brussels, BE (Prof. Thierry Boon and Prof. Pierre van der Bruggen).
Nowadays at the GHDC, Javier routinely conducts immuno-oncology research projects such as the one supported by the Belgian Cancer Foundation and the Belgian Federal Cancer Plan aiming at exploring the interactions between early stage cancers and the immune system and at identifying new prognostic or predictive biomarkers to better select patients who will benefit from immunomodulatory treatments.
Javier is the inventor of the innovative quantitative TCR Seq analysis platform for immuno-monitoring of cancer patients.
Since 2021 Javier is the Medical advisor of Seqalis, part of IPG Group, Gosselies, assisting in the deployment of the qTCR-Seq platform.

For over 10 years he has been following closely the evolutions in the field of healthcare innovation and biotechnology.